Physiomics Share Discussion Threads

[hazelst] 12/3/2018 14:39

So glad I bought these on Friday.

[alia] 12/3/2018 14:38

we know how these rises

[spacedust] 12/3/2018 14:37

No dilution to sp

[spacedust] 12/3/2018 14:34

Me too. Come on Stig this looks super now

[markth126] 12/3/2018 14:32

Based on what? Gut feeling? Hey I hope your right tho!

[the stigologist] 12/3/2018 14:31

50-100p back on (within weeks I reckon)

[hazelst] 12/3/2018 14:29

Looking good!

[maytrees] 12/3/2018 14:20

Some decent buying so far this pm.

[the stigologist] 12/3/2018 13:22

Think this NON-RNS has really set the tone.

I wonder what is coming.

Go back and read October 2nd RNS.

Nobody took much notice.

2 months later we went from 1p to 32p

I strongly expect within 2 months of the February Interims we will see a similar type of move

5p... to ? 50p ? 100p ?

[davevt] 12/3/2018 10:52

Who ever wrote that twitter post didn't realise the REQUIREMENTS for applying for funding in the medical field. Go and look it up, it has to 'involve micro or small businesses'....ie most likely not ROLLING IN IT. The other companies on the list are in different categories with totally different stipulations. Typical rampers not checking facts before posting.

[davevt] 12/3/2018 10:46

'paid 500k for access to PYC expertise ' Jack twisting words there, 'no access', just what they expected to spend over a year. And seeing as they already spend about 100k a year, and the 500k is euros, that's really an extra 350k a year.

[the stigologist] 12/3/2018 09:19

The personalised medicine initiative is aimed at improving the successful treatment of cancer patients, turning dosing and management from being an art form to being a science. Following the Company's early success in winning a competitive Innovate UK grant in this space and encouraging results from its feasibility project (due to complete in January 2018), the Company has identified other non-dilutive funding opportunities in this space and intends to pursue these where appropriate. There appears to be a significant level of investor and government interest in developing technologies in this area.

[spacedust] 12/3/2018 09:07

Nothing on advfn

[spacedust] 12/3/2018 09:04

What time was this issued?

[the stigologist] 12/3/2018 08:34

"The project was formally signed off by Innovate UK following a final project meeting in February this year"

February also the closing date for the next round of funding they could apply for.

One would expect given success of the initial project then Innovate UK and/or any other investors will most likely respond positively to the next stage of the project.

[the stigologist] 12/3/2018 07:56

Seeing as Merck paid 500k for access to PYC expertise before this it does bode very well indeed for the future

[ayl30] 12/3/2018 07:37

Thanks, yes encouraging

[the stigologist] 12/3/2018 07:33

Key bit...


The results and learnings from the project have potential applications in both the Company's existing business advising R&D based pharmaceutical and biotech companies as well as in the emerging field of personalised cancer treatment. In order to further develop the technology the company is actively seeking additional grants in this space (as originally announced in October 2017).

The Company believes that the field of personalised or stratified cancer treatment, whether in R&D or in clinical practice will continue to gain importance in the short to medium term and that the Company is well positioned to contribute towards its development.

[the stigologist] 12/3/2018 07:31

FE Investegate |Physiomics PLC Announcements
RNS Number : 3209H
Physiomics PLC
12 March 2018
12th March 2018

Physiomics plc

("Physiomics") or ("the Company")

Completion of Innovate UK Grant Project on Personalised Treatment of Oesophageal Cancer

Physiomics plc (AIM: PYC), a provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry, is pleased to confirm that is has successfully completed the Innovate UK grant project announced in January 2017. The project was formally signed off by Innovate UK following a final project meeting in February this year. The Company can confirm that, in line with expectations, it received total funding of £131k from Innovate UK over the course of the project, of which around £81k will be recognised in the Company's current financial year.

The project "Decision Support System For Stratified Cancer Treatment" analysed data from over 400 oesophageal cancer patients to determine patient and disease specific factors that could help guide treatment to achieve the best outcomes, and created a tool for healthcare professionals to visualise this data. The project was conducted in collaboration with Prof Mark Middleton of Oxford University and the Oxford AHSN, and the Company intends to publicise the key results and findings of the project through an abstract, poster and other publications over the course of 2018 (further announcements will be forthcoming).

The results and learnings from the project have potential applications in both the Company's existing business advising R&D based pharmaceutical and biotech companies as well as in the emerging field of personalised cancer treatment. In order to further develop the technology the company is actively seeking additional grants in this space (as originally announced in October 2017).

The Company believes that the field of personalised or stratified cancer treatment, whether in R&D or in clinical practice will continue to gain importance in the short to medium term and that the Company is well positioned to contribute towards its development.

Enquiries:

Physiomics plc

Dr Jim Millen, CEO

[phone]

WH Ireland Limited (nomad)

Katy Mitchell/James Sinclair-Ford

[phone]

Hybridan LLP (broker)

Claire Louise Noyce

[phone]

About Physiomics plc

Physiomics plc (AIM: PYC) is a solutions provider to the R&D-based pharmaceutical and biotechnology industry with a focus on oncology. The Company's Virtual Tumour technology uses computer modelling to predict the effects of cancer drugs and treatments to improve the success rate of drug discovery and development projects while reducing time and cost. The predictive capability of Virtual Tumour has been confirmed by 55 projects, involving over 25 targets and 60 drugs.

Based in Oxford, UK, the Company works with clients worldwide to support their pre-clinical and clinical oncology development programs. Its team of scientists and computer modelling experts provide bespoke solutions encompassing data, analytics and insight.

Physiomics' senior management has academic and commercial expertise, including over 90 years collectively of working in oncology and/or computational biology and over 100 publications in peer reviewed journals.

About Innovate UK

Innovate UK is the UK's innovation-agency. It works with people, companies and partner organisations to find and drive the science and technology innovations that will grow the UK economy. For further information visit www.innovateuk.gov.uk


This information is provided by RNS

[ayl30] 12/3/2018 07:25

Can't see a rns?

[spacedust] 11/3/2018 16:34

Pwhite are you around? I need your opinion on another share if that's ok?

[spacedust] 09/3/2018 23:07

Jim the famous seller Who has confidence in the company